Arthur W. Bracey, MD
See Publications

Education

  • Medical School:

    Georgetown University School of Medicine

  • Internship:

    Georgetown University Hospital

  • Residency:

    Georgetown University Hospital

Academic & Clinical Affiliations

  • Baylor St. Luke's Medical Center
  • Board of Trustees, Harris Health System

Honors, Awards and Memberships

Publications

4862227 KIXH6H5E 1 alternatives-to-animal-experimentation 10 date desc Bracey 1836 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%227BBX7DUS%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bracey%22%2C%22parsedDate%22%3A%222023-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BBracey%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20%282023%29.%20A%20river%20runs%20through%20it%3A%20Reflections%20of%20blood%20flow%2C%20teams%2C%20and%20lives.%20%26lt%3Bi%26gt%3BTransfusion%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B63%26lt%3B%5C%2Fi%26gt%3B%2C%20908%26%23x2013%3B911.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftrf.17351%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftrf.17351%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20river%20runs%20through%20it%3A%20Reflections%20of%20blood%20flow%2C%20teams%2C%20and%20lives%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Bracey%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Ftrf.17351%22%2C%22ISSN%22%3A%221537-2995%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%2C%225WVJH2TN%22%5D%2C%22dateModified%22%3A%222023-06-08T13%3A53%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22XJXPDN6H%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patel%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPatel%2C%20B.%2C%20Diaz-Gomez%2C%20J.%20L.%2C%20Ghanta%2C%20R.%20K.%20et%20al.%20%282021%29.%20Management%20of%20extracorporeal%20membrane%20oxygenation%20for%20postcardiotomy%20cardiogenic%20shock.%20%26lt%3Bi%26gt%3BAnesthesiology%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B135%26lt%3B%5C%2Fi%26gt%3B%2C%20497%26%23x2013%3B507.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FALN.0000000000003876%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FALN.0000000000003876%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20of%20extracorporeal%20membrane%20oxygenation%20for%20postcardiotomy%20cardiogenic%20shock%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhoumesh%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20L.%22%2C%22lastName%22%3A%22Diaz-Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ravi%20K.%22%2C%22lastName%22%3A%22Ghanta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%20W.%22%2C%22lastName%22%3A%22Bracey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subhasis%22%2C%22lastName%22%3A%22Chatterjee%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Sept%2001%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FALN.0000000000003876%22%2C%22ISSN%22%3A%221528-1175%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%2C%22BQPL6CIB%22%2C%22VCK5HVUS%22%2C%22AFDZBLNB%22%5D%2C%22dateModified%22%3A%222022-02-04T15%3A40%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22YL4K5J2C%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pandey%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPandey%2C%20S.%2C%20Belanger%2C%20G.%20A.%2C%20Rajbhandary%2C%20S.%20et%20al.%20%282021%29.%20A%20survey%20of%20US%20hospitals%20on%20platelet%20inventory%20management%2C%20transfusion%20practice%2C%20and%20platelet%20availability.%20%26lt%3Bi%26gt%3BTransfusion%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B61%26lt%3B%5C%2Fi%26gt%3B%2C%202611%26%23x2013%3B2620.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftrf.16561%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftrf.16561%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20survey%20of%20US%20hospitals%20on%20platelet%20inventory%20management%2C%20transfusion%20practice%2C%20and%20platelet%20availability%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suchitra%22%2C%22lastName%22%3A%22Pandey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%20A.%22%2C%22lastName%22%3A%22Belanger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srijana%22%2C%22lastName%22%3A%22Rajbhandary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20S.%22%2C%22lastName%22%3A%22Cohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20J.%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%20W.%22%2C%22lastName%22%3A%22Bracey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%20M.%22%2C%22lastName%22%3A%22Katz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%20E.%22%2C%22lastName%22%3A%22Menitove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20D.%22%2C%22lastName%22%3A%22Mintz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20R.%22%2C%22lastName%22%3A%22Gammon%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20A%20survey%20of%20US%20hospitals%20was%20conducted%20to%20increase%20our%20understanding%20of%20the%20current%20state%20of%20platelet%20%28PLT%29%20practice%20and%20supply.%20The%20survey%20captures%20information%20on%20transfusion%20practice%20and%20inventory%20management%2C%20including%20stock%20levels%2C%20outdate%20rates%2C%20ability%20to%20return%20or%20transfer%20PLTs%2C%20and%20low%20dose%20PLTs.%20Notably%2C%20the%20survey%20also%20elucidates%20PLT%20availability%20challenges%20and%20impact%20to%20patient%20care.%5CnSTUDY%20DESIGN%20AND%20METHODS%3A%20A%2027%20question%20online%20survey%20was%20distributed%20directly%20to%20over%20995%20US%20hospitals%20and%20indirectly%20through%20blood%20centers%20to%20many%20more%20between%20September%2027%20and%20October%2025%2C%202019.%20Descriptive%20statistics%20were%20used%20for%20respondent%20characteristics.%20Bivariate%20analysis%20was%20performed%20and%20correlation%20coefficients%2C%20chi%20square%20tests%2C%20and%20p%20values%20determined%20statistical%20significance%20of%20relationships%20between%20variables.%5CnRESULTS%3A%20Four%20hundred%20and%20eighty-one%20hospitals%20completed%20the%20survey%20of%20which%2021.6%25%2C%2053.2%25%2C%20and%2025.2%25%20were%20characterized%20as%20small%2C%20medium%2C%20and%20large%20hospitals%2C%20respectively.%20Some%20key%20observations%20from%20this%20survey%20include%3A%20%281%29%20there%20is%20an%20opportunity%20for%20greater%20adherence%20to%20evidence-based%20guidelines%3B%20%282%29%20higher%20outdate%20rates%20occur%20in%20hospitals%20stocking%20less%20than%20five%20PLTs%20and%20the%20ability%20to%20return%20or%20transfer%20PLTs%20lowers%20outdates%3B%20%283%29%20use%20of%20low%20dose%20apheresis%20PLTs%20varies%3B%20and%20%284%29%20decreased%20PLT%20availability%20is%20commonly%20reported%2C%20especially%20in%20hospitals%20with%20high%20usage%2C%20and%20can%20lead%20to%20delays%20in%20transfusions%20or%20surgeries.%5CnCONCLUSION%3A%20This%20survey%20represents%20a%20comprehensive%20national%20assessment%20of%20inventory%20management%20practices%20and%20PLT%20availability%20challenges%20in%20US%20hospitals.%20Findings%20from%20this%20survey%20can%20be%20used%20to%20guide%20further%20research%2C%20help%20shape%20future%20guidance%20for%20industry%2C%20and%20assist%20with%20policy%20decisions.%22%2C%22date%22%3A%222021-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Ftrf.16561%22%2C%22ISSN%22%3A%221537-2995%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%5D%2C%22dateModified%22%3A%222023-01-12T22%3A09%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22ZJJ5Y3PU%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carson%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCarson%2C%20J.%20L.%2C%20Ness%2C%20P.%20M.%2C%20Pagano%2C%20M.%20B.%20et%20al.%20%282021%29.%20Plasma%20trial%3A%20Pilot%20randomized%20clinical%20trial%20to%20determine%20safety%20and%20efficacy%20of%20plasma%20transfusions.%20%26lt%3Bi%26gt%3BTransfusion%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B61%26lt%3B%5C%2Fi%26gt%3B%2C%202025%26%23x2013%3B2034.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftrf.16508%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftrf.16508%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasma%20trial%3A%20Pilot%20randomized%20clinical%20trial%20to%20determine%20safety%20and%20efficacy%20of%20plasma%20transfusions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20L.%22%2C%22lastName%22%3A%22Carson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20M.%22%2C%22lastName%22%3A%22Ness%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%20B.%22%2C%22lastName%22%3A%22Pagano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%20S.%22%2C%22lastName%22%3A%22Philipp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%20W.%22%2C%22lastName%22%3A%22Bracey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Mori%22%2C%22lastName%22%3A%22Brooks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20L.%22%2C%22lastName%22%3A%22Nosher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hogshire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helaine%22%2C%22lastName%22%3A%22Noveck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darrell%20J.%22%2C%22lastName%22%3A%22Triulzi%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Plasma%20is%20frequently%20administered%20to%20patients%20with%20prolonged%20INR%20prior%20to%20invasive%20procedures.%20However%2C%20there%20is%20limited%20evidence%20evaluating%20efficacy%20and%20safety.%5CnSTUDY%20DESIGN%20AND%20METHODS%3A%20We%20performed%20a%20pilot%20trial%20in%20hospitalized%20patients%20with%20INR%20between%201.5%20and%202.5%20undergoing%20procedures%20conducted%20outside%20the%20operating%20room.%20We%20excluded%20patients%20undergoing%20procedures%20proximal%20to%20the%20central%20nervous%20system%2C%20platelet%20counts%20%26lt%3B40%2C000%5C%2F%5Cu03bcl%2C%20or%20congenital%20or%20acquired%20coagulation%20disorders%20unresponsive%20to%20plasma.%20We%20randomly%20allocated%20patients%20stratified%20by%20hospital%20and%20history%20of%20cirrhosis%20to%20receive%20plasma%20transfusion%20%2810-15%5Cu2009cc%5C%2Fkg%29%20or%20no%20transfusion.%20The%20primary%20outcome%20was%20change%20in%20hemoglobin%20concentration%20within%202%5Cu2009days%20of%20procedure.%5CnRESULTS%3A%20We%20enrolled%2057%20patients%2C%20mean%20age%2056.0%2C%2034%20%2859.6%25%29%20with%20cirrhosis%2C%20and%20mean%20INR%201.92%20%28SD%5Cu00a0%3D%5Cu00a00.27%29.%20In%20the%20intention%20to%20treat%20analysis%2C%20there%20were%2010%20of%2027%20%2838.5%25%29%20participants%20in%20the%20plasma%20arm%20with%20a%20post%20procedure%20INR%20%26lt%3B1.5%20and%20one%20of%2030%20%283.6%25%29%20in%20the%20no%20treatment%20arm%20%28p%5Cu2009%26lt%3B%5Cu2009.01%29.%20The%20mean%20INR%20after%20receiving%20plasma%20transfusion%20was%20-0.24%20%28SD%200.26%29%20lower%20than%20baseline.%20The%20change%20from%20pre-procedure%20hemoglobin%20level%20to%20lowest%20level%20within%202%5Cu2009days%20was%20-0.6%20%28SD%5Cu00a0%3D%5Cu00a01.0%29%20in%20the%20plasma%20transfusion%20arm%20and%20-0.4%20%28SD%5Cu00a0%3D%5Cu00a00.6%29%20in%20the%20no%20transfusion%20arm%20%28p%5Cu00a0%3D%5Cu00a0.29%29.%20Adverse%20outcomes%20were%20uncommon.%5CnDISCUSSION%3A%20We%20found%20no%20differences%20in%20change%20in%20hemoglobin%20concentration%20in%20those%20treated%20with%20plasma%20compared%20to%20no%20treatment.%20The%20change%20in%20INR%20was%20small%20and%20corrected%20to%20less%20than%201.5%20in%20minority%20of%20patients.%20Large%20trials%20are%20required%20to%20establish%20if%20plasma%20is%20safe%20and%20efficacious.%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Ftrf.16508%22%2C%22ISSN%22%3A%221537-2995%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%5D%2C%22dateModified%22%3A%222021-08-20T17%3A08%3A26Z%22%7D%7D%2C%7B%22key%22%3A%223IBSAC2U%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maffei%20et%20al.%22%2C%22parsedDate%22%3A%222020-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaffei%2C%20S.%20R.%2C%20Lamba%2C%20H.%20K.%2C%20Mensah%2C%20C.%20K.%20et%20al.%20%282020%29.%20Plasmapheresis%20in%20patients%20with%20heparin-induced%20thrombocytopenia%20requiring%20ventricular%20assist%20device.%20%26lt%3Bi%26gt%3BAnn%20Thorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B109%26lt%3B%5C%2Fi%26gt%3B%2C%20e439%26%23x2013%3Be440.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2019.09.056%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2019.09.056%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasmapheresis%20in%20patients%20with%20heparin-induced%20thrombocytopenia%20requiring%20ventricular%20assist%20device%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salvador%20R.%22%2C%22lastName%22%3A%22Maffei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harveen%20K.%22%2C%22lastName%22%3A%22Lamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cassius%20Kwasi%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Bracey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Civitello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reynolds%22%2C%22lastName%22%3A%22Delgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leo%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20H.%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20A.%22%2C%22lastName%22%3A%22Morgan%22%7D%5D%2C%22abstractNote%22%3A%22Anticoagulation%20with%20unfractionated%20heparin%20is%20vital%20to%20reduce%20the%20risk%20of%20thromboembolic%20events%20during%20cardiopulmonary%20bypass%20and%20left%20ventricular%20assist%20device%20placement.%20However%20patients%20with%20heparin-induced%20thrombocytopenia%20are%20at%20risk%20of%20developing%20immune-mediated%20thrombotic%20events.%20We%20describe%202%20patients%20with%20heparin-induced%20thrombocytopenia%20confirmed%20via%20serotonin%20release%20assay%20who%20were%20successfully%20treated%20with%20plasmapheresis%20exchange%20before%20left%20ventricular%20assist%20device%20placement.%22%2C%22date%22%3A%22Jun%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.athoracsur.2019.09.056%22%2C%22ISSN%22%3A%221552-6259%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%22KIXH6H5E%22%2C%229FBUJBMU%22%2C%22TIPQ3BD5%22%2C%22AAQ89W3S%22%2C%22S7WF6DG3%22%5D%2C%22dateModified%22%3A%222022-01-25T15%3A05%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22PW9AA3FH%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Preventza%20et%20al.%22%2C%22parsedDate%22%3A%222020-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPreventza%2C%20O.%2C%20Anton%2C%20J.%20and%20%26lt%3Bstrong%26gt%3BBracey%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20%282020%29.%20Commentary%3A%20Can%20we%20make%20autologous%20blood%20transfusion%20a%20reality%20in%20high-risk%20cardiac%20surgery%20cases%3F%20%26lt%3Bi%26gt%3BJ%20Thorac%20Cardiovasc%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B159%26lt%3B%5C%2Fi%26gt%3B%2C%202298%26%23x2013%3B2299.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jtcvs.2019.05.018%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jtcvs.2019.05.018%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Commentary%3A%20Can%20we%20make%20autologous%20blood%20transfusion%20a%20reality%20in%20high-risk%20cardiac%20surgery%20cases%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ourania%22%2C%22lastName%22%3A%22Preventza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Anton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Bracey%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jun%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jtcvs.2019.05.018%22%2C%22ISSN%22%3A%221097-685X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SQD2CTYV%22%2C%22KIXH6H5E%22%2C%224TINQULR%22%5D%2C%22dateModified%22%3A%222022-01-22T13%3A05%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22XQWEJDDG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rali%20et%20al.%22%2C%22parsedDate%22%3A%222020-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRali%2C%20A.%20S.%2C%20Salem%2C%20A.%20M.%2C%20Gebre%2C%20M.%20et%20al.%20%282020%29.%20Viscoelastic%20haemostatic%20assays%20in%20cardiovascular%20critical%20care.%20%26lt%3Bi%26gt%3BCard%20Fail%20Rev%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B7%26lt%3B%5C%2Fi%26gt%3B%2C%20e01.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.15420%5C%2Fcfr.2020.22%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.15420%5C%2Fcfr.2020.22%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Viscoelastic%20haemostatic%20assays%20in%20cardiovascular%20critical%20care%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aniket%20S.%22%2C%22lastName%22%3A%22Rali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%20M.%22%2C%22lastName%22%3A%22Salem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melat%22%2C%22lastName%22%3A%22Gebre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Taylor%20M.%22%2C%22lastName%22%3A%22Garies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siva%22%2C%22lastName%22%3A%22Taduru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%20W.%22%2C%22lastName%22%3A%22Bracey%22%7D%5D%2C%22abstractNote%22%3A%22The%20initiation%20and%20management%20of%20anticoagulation%20is%20a%20fundamental%20practice%20for%20a%20wide%20variety%20of%20indications%20in%20cardiovascular%20critical%20care%2C%20including%20the%20management%20of%20patients%20with%20acute%20MI%2C%20stroke%20prevention%20in%20patients%20with%20AF%20or%20mechanical%20valves%2C%20as%20well%20as%20the%20prevention%20of%20device%20thrombosis%20and%20thromboembolic%20events%20with%20the%20use%20of%20mechanical%20circulatory%20support%20and%20ventricular%20assist%20devices.%20The%20frequent%20use%20of%20antiplatelet%20and%20anticoagulation%20therapy%2C%20in%20addition%20to%20the%20presence%20of%20concomitant%20conditions%20that%20may%20lead%20to%20a%20propensity%20to%20bleed%2C%20such%20as%20renal%20and%20liver%20dysfunction%2C%20present%20unique%20challenges.%20The%20use%20of%20viscoelastic%20haemostatic%20assays%20provides%20an%20additional%20tool%20allowing%20clinicians%20to%20strike%20a%20delicate%20balance%20of%20attaining%20adequate%20anticoagulation%20while%20minimising%20the%20risk%20of%20bleeding%20complications.%20In%20this%20review%2C%20the%20authors%20discuss%20the%20role%20that%20viscoelastic%20haemostatic%20assay%20plays%20in%20cardiac%20populations%20%28including%20cardiac%20surgery%2C%20heart%20transplantation%2C%20extracorporeal%20membrane%20oxygenation%2C%20acute%20coronary%20syndrome%20and%20left%20ventricular%20assist%20devices%29%2C%20and%20identify%20areas%20in%20need%20of%20further%20study.%22%2C%22date%22%3A%222020-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.15420%5C%2Fcfr.2020.22%22%2C%22ISSN%22%3A%222057-7540%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%5D%2C%22dateModified%22%3A%222021-08-20T17%3A10%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22AI62YAV8%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alrabeh%20et%20al.%22%2C%22parsedDate%22%3A%222019-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAlrabeh%2C%20R.%2C%20Korte%2C%20L.%2C%20Reyes%2C%20M.%20et%20al.%20%282019%29.%20Long-term%20experience%20with%20rapid%20screening%20for%20platelet%20bacterial%20contamination%20in%20a%20high-volume%20transfusion%20service.%20%26lt%3Bi%26gt%3BAnn%20Clin%20Lab%20Sci%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B49%26lt%3B%5C%2Fi%26gt%3B%2C%20748%26%23x2013%3B755%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20experience%20with%20rapid%20screening%20for%20platelet%20bacterial%20contamination%20in%20a%20high-volume%20transfusion%20service%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reem%22%2C%22lastName%22%3A%22Alrabeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Korte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meredith%22%2C%22lastName%22%3A%22Reyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Hartwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Bracey%22%7D%5D%2C%22abstractNote%22%3A%22Bacterial%20sepsis%20after%20platelet%20transfusion%20is%20a%20major%20cause%20of%20transfusion-transmitted%20infections%20in%20the%20US.%20The%20Food%20and%20Drug%20Administration%20%28FDA%29%20recommends%20performing%20quality%20control%20for%20platelet%20bacterial%20detection%20on%20days%204%20and%205%20before%20platelet%20transfusion.%20We%20assessed%20the%20feasibility%20of%20implementing%20the%20Pan%20Genera%20Detection%20%28PGD%29%20test%2C%20an%20FDA-approved%20immunoassay%20for%20platelet%20bacterial%20detection%2C%20for%20the%20primary%20and%20secondary%20bacterial%20screening%20of%20platelet%20units%20in%20a%20high-volume%20setting.%20Records%20were%20reviewed%20from%20January%202010%20through%20December%202015.%20All%20apheresis%20platelets%20underwent%20primary%20screening%20by%20using%20culture%20methods.%20Additional%20screening%20with%20the%20PGD%20test%20was%20performed%20daily%20until%20February%202013%2C%20when%20PGD%20testing%20of%20apheresis%20platelets%20was%20performed%20at%20the%20start%20of%20storage%20day%205.%20In%20April%202015%2C%20PGD%20testing%20of%20apheresis%20platelet%20products%20was%20performed%20at%20the%20start%20of%20storage%20day%204.%20Post-storage%20pooled%20whole%20blood-derived%20platelets%20were%20screened%20by%20using%20the%20PGD%20test%20on%20the%20day%20of%20use.%20During%20the%206-year%20study%20period%2C%2016%2C839%20PGD%20tests%20were%20performed.%20If%20the%20PGD%20test%20was%20reactive%2C%20repeat%20PGD%20testing%20was%20performed.%20In%20cases%20of%20repeat%20reactivity%2C%20units%20were%20quarantined%20and%20cultured.%20Initially%2C%2042%20%280.25%25%29%20tests%20were%20reactive%3B%2026%5C%2F42%20%2861.91%25%29%20were%20repeatedly%20reactive%20and%20resulted%20in%20an%20overall%20PGD%20repeat%20reactivity%20rate%20of%200.15%25.%20Only%20one%20sample%20grew%20coagulase-negative%20Staphylococcus%20No%20transfusion-transmitted%20infections%20were%20reported.%20The%20PGD%20bacterial%20detection%20assay%20was%20feasible%20and%20efficient%20in%20our%20high-volume%20transfusion%20service.%22%2C%22date%22%3A%22Nov%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%221550-8080%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%5D%2C%22dateModified%22%3A%222020-01-14T21%3A24%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22UPI4EWSS%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Colman%20et%20al.%22%2C%22parsedDate%22%3A%222019-08%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BColman%2C%20E.%2C%20Yin%2C%20E.%20B.%2C%20Laine%2C%20G.%20et%20al.%20%282019%29.%20Evaluation%20of%20a%20heparin%20monitoring%20protocol%20for%20extracorporeal%20membrane%20oxygenation%20and%20review%20of%20the%20literature.%20%26lt%3Bi%26gt%3BJ%20Thorac%20Dis%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B11%26lt%3B%5C%2Fi%26gt%3B%2C%203325%26%23x2013%3B3335.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21037%5C%2Fjtd.2019.08.44%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21037%5C%2Fjtd.2019.08.44%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20a%20heparin%20monitoring%20protocol%20for%20extracorporeal%20membrane%20oxygenation%20and%20review%20of%20the%20literature%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Colman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%20B.%22%2C%22lastName%22%3A%22Yin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%22%2C%22lastName%22%3A%22Laine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subhasis%22%2C%22lastName%22%3A%22Chatterjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siavosh%22%2C%22lastName%22%3A%22Saatee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Patrick%22%2C%22lastName%22%3A%22Herlihy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meredith%20A.%22%2C%22lastName%22%3A%22Reyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%20W.%22%2C%22lastName%22%3A%22Bracey%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20Bleeding%20complications%20are%20common%20with%20extracorporeal%20membrane%20oxygenation%20%28ECMO%29.%20We%20investigated%20whether%20a%20heparin%20monitoring%20protocol%20using%20activated%20partial%20thromboplastin%20time%20%28aPTT%29%20and%20thromboelastography%20%28TEG%29%20affected%20clinical%20outcomes.%5CnMethods%3A%20This%20retrospective%20chart%20review%20stratified%20cohorts%20by%20study%20interval%3A%20pre-protocol%20%28January%202016-March%202017%29%20or%20post-protocol%20%28March%202017-December%202017%29.%20The%20protocol%20defined%20therapeutic%20anticoagulation%20as%20aPTT%20of%2060-80%20seconds%20and%20a%20TEG%20reaction%20%28TEG-R%29%20time%20of%202-4%5Cu00d7%20baseline%3B%20pre-protocol%20management%20used%20aPTT%20alone.%20The%20primary%20endpoints%20were%20the%20rates%20of%20bleeding%20and%20thrombotic%20events%20%28clinical%5C%2Fdevice%20thrombosis%29%20as%20defined%20by%20Extracorporeal%20Life%20Support%20Organization%20%28ELSO%29%20guidelines.%20Secondary%20endpoints%20included%20time%20in%20therapeutic%20aPTT%20range%2C%20rate%20of%20physician%20compliance%20with%20the%20protocol%2C%20time%20to%20heparin%20initiation%2C%20intensive%20care%20unit%20length%20of%20stay%2C%20mortality%2C%20and%20antithrombin%20III%20%28ATIII%29%20supplementation.%5CnResults%3A%20The%20pre-protocol%20%28n%3D72%29%20and%20post-protocol%20%28n%3D51%29%20groups%20%28age%2060%5Cu00b112%20years%3B%2080%25%20on%20venoarterial%20ECMO%3B%20average%20ECMO%20duration%20of%206%20days%29%20showed%20no%20difference%20in%20baseline%20characteristics.%20Major%20bleeding%20events%20occurred%20in%2069%25%20of%20pre-protocol%20patients%2C%20versus%2067%25%20of%20post-protocol%20patients%20%28P%3D0.85%29.%20The%20post-protocol%20group%20had%20fewer%20retroperitoneal%20bleeds%20%28P%3D0.01%29%20and%20had%20a%20non-significantly%20lower%20rate%20of%20pulmonary%20or%20central%20nervous%20system%20%28CNS%29%20bleeding%20%28P%3D0.07%29.%20Thrombotic%20events%20occurred%20in%2021%25%20of%20the%20pre-protocol%20group%2C%20versus%2028%25%20of%20the%20post-protocol%20group%20%28P%3D0.39%29.%20Mortality%20during%20ECMO%20support%20was%20significantly%20lower%20in%20the%20post-protocol%20group%20%2856.9%25%20vs.%2033.3%25%2C%20P%3D0.01%29.%20The%20thrombosis%20rate%20was%20higher%20in%20patients%20who%20received%20ATIII%20than%20in%20those%20who%20did%20not%20%2848.2%25%20vs.%2015.9%25%2C%20P%26lt%3B0.01%29.%5CnConclusions%3A%20Major%20bleeding%20did%20not%20differ%20between%20the%20treatment%20groups.%20However%2C%20we%20observed%20significantly%20less%20mortality%20and%20retroperitoneal%20bleeding%20in%20the%20post-protocol%20group%2C%20suggesting%20an%20important%20gain%20from%20the%20intervention.%20Further%20study%20of%20the%20value%20of%20ATIII%20supplementation%20in%20ECMO%20patients%20is%20needed%20since%20we%20observed%20that%20a%20lower%20baseline%20ATIII%20level%20may%20indicate%20higher%20risk%20for%20thrombosis.%22%2C%22date%22%3A%22Aug%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.21037%5C%2Fjtd.2019.08.44%22%2C%22ISSN%22%3A%222072-1439%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%2C%22VCK5HVUS%22%5D%2C%22dateModified%22%3A%222022-01-24T15%3A46%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22663Y9AFS%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bracey%20et%20al.%22%2C%22parsedDate%22%3A%222018-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BBracey%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%2C%20Shatila%2C%20W.%20and%20Wilson%2C%20J.%20%282018%29.%20Bleeding%20in%20patients%20receiving%20non-vitamin%20K%20oral%20anticoagulants%3A%20clinical%20trial%20evidence.%20%26lt%3Bi%26gt%3BTher%20Adv%20Cardiovasc%20Dis%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%2C%20361%26%23x2013%3B380.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1753944718801554%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1753944718801554%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bleeding%20in%20patients%20receiving%20non-vitamin%20K%20oral%20anticoagulants%3A%20clinical%20trial%20evidence%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Bracey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wassim%22%2C%22lastName%22%3A%22Shatila%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Wilson%22%7D%5D%2C%22abstractNote%22%3A%22In%20optimizing%20anticoagulation%20therapy%2C%20it%20is%20essential%20to%20balance%20treatment%20efficacy%20with%20the%20major%20adverse%20effect%20of%20anticoagulant%20treatment%2C%20bleeding%20risk.%20This%20narrative%20review%20examines%20the%20efficacy%20and%20safety%20of%20the%20non-vitamin%20K%20antagonist%20oral%20anticoagulants%20%28NOACs%29%20dabigatran%2C%20rivaroxaban%2C%20apixaban%2C%20and%20edoxaban%20compared%20with%20standard%20anticoagulation%20or%20placebo.%20NOAC%20therapies%20provide%20equivalent%20to%20superior%20protection%20versus%20standard%20therapy%2C%20with%20similar%20or%20superior%20safety%2C%20and%20potential%20benefits%20in%20convenience.%20We%20will%20review%20the%20phase%20III%20evidence%20for%20each%20of%20the%20available%20NOACs%20in%20different%20antithrombotic%20indications%2C%20including%20atrial%20fibrillation%20%28in%20the%20absence%20of%20significant%20mitral%20stenosis%20or%20mechanical%20heart%20valves%29%3B%20prophylaxis%20of%20venous%20thromboembolism%20%28VTE%29%20in%20patients%20undergoing%20orthopedic%20surgery%3B%20and%20acute%20and%20long-term%20treatment%20of%20VTE.%20Further%2C%20we%20will%20illustrate%20scenarios%20in%20which%20the%20evidence%20is%20stronger%20for%20a%20particular%20agent%20in%20the%20context%20of%20the%20overall%20positive%20safety%20and%20efficacy%20profile%20of%20NOACs%20in%20general.%20Limitations%20of%20the%20factor%20Xa%20inhibitors%20include%20the%20lack%20of%20a%20specific%20antidote%20in%20case%20of%20a%20bleeding%20emergency%20%28an%20approved%20agent%20is%20available%20for%20reversing%20the%20effect%20of%20the%20direct%20thrombin%20inhibitor%29.%20We%20discuss%20the%20options%20for%20mitigating%20bleeding%20and%20describe%20the%20ongoing%20developments%20towards%20specific%20reversal%20agents.%20In%20conclusion%2C%20the%20available%20data%20for%20efficacy%20and%20safety%2C%20together%20with%20reliable%20pharmacokinetics%20obviating%20the%20need%20for%20regular%20monitoring%2C%20indicate%20that%20NOACs%20may%20offer%20substantial%20benefits%20for%20patients%20with%20nonvalvular%20atrial%20fibrillation%20or%20VTE.%22%2C%22date%22%3A%22Dec%202018%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1753944718801554%22%2C%22ISSN%22%3A%221753-9455%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KIXH6H5E%22%5D%2C%22dateModified%22%3A%222019-01-02T21%3A49%3A46Z%22%7D%7D%5D%7D
Bracey, A. (2023). A river runs through it: Reflections of blood flow, teams, and lives. Transfusion 63, 908–911. https://doi.org/10.1111/trf.17351.
Patel, B., Diaz-Gomez, J. L., Ghanta, R. K. et al. (2021). Management of extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock. Anesthesiology 135, 497–507. https://doi.org/10.1097/ALN.0000000000003876.
Pandey, S., Belanger, G. A., Rajbhandary, S. et al. (2021). A survey of US hospitals on platelet inventory management, transfusion practice, and platelet availability. Transfusion 61, 2611–2620. https://doi.org/10.1111/trf.16561.
Carson, J. L., Ness, P. M., Pagano, M. B. et al. (2021). Plasma trial: Pilot randomized clinical trial to determine safety and efficacy of plasma transfusions. Transfusion 61, 2025–2034. https://doi.org/10.1111/trf.16508.
Maffei, S. R., Lamba, H. K., Mensah, C. K. et al. (2020). Plasmapheresis in patients with heparin-induced thrombocytopenia requiring ventricular assist device. Ann Thorac Surg 109, e439–e440. https://doi.org/10.1016/j.athoracsur.2019.09.056.
Preventza, O., Anton, J. and Bracey, A. (2020). Commentary: Can we make autologous blood transfusion a reality in high-risk cardiac surgery cases? J Thorac Cardiovasc Surg 159, 2298–2299. https://doi.org/10.1016/j.jtcvs.2019.05.018.
Rali, A. S., Salem, A. M., Gebre, M. et al. (2020). Viscoelastic haemostatic assays in cardiovascular critical care. Card Fail Rev 7, e01. https://doi.org/10.15420/cfr.2020.22.
Alrabeh, R., Korte, L., Reyes, M. et al. (2019). Long-term experience with rapid screening for platelet bacterial contamination in a high-volume transfusion service. Ann Clin Lab Sci 49, 748–755
Colman, E., Yin, E. B., Laine, G. et al. (2019). Evaluation of a heparin monitoring protocol for extracorporeal membrane oxygenation and review of the literature. J Thorac Dis 11, 3325–3335. https://doi.org/10.21037/jtd.2019.08.44.
Bracey, A., Shatila, W. and Wilson, J. (2018). Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. Ther Adv Cardiovasc Dis 12, 361–380. https://doi.org/10.1177/1753944718801554.